Groundbreaking Therapy for Sickle Cell Disease Achieves Remarkable Long-Term Results
In a momentous advancement for the treatment of sickle cell disease (SCD), CorrectSequence Therapeutics Co., Ltd. has reported outstanding outcomes from its pioneering high-precision base-editing therapy, CS-206. This innovative approach has demonstrated a durable and VOC-free efficacy over a period exceeding 15 months in a clinical trial involving a 21-year-old woman from Nigeria, who had suffered from recurrent vaso-occlusive crises (VOCs).
The patient underwent treatment in February 2025 and has remained free from VOCs and anemia for 13 consecutive months, achieving the primary efficacy endpoint set by the study. Following the engraftment of CS-206, the patient's hematologic profile improved dramatically. Neutrophils were detected as early as Day 13, and by Day 21, her platelet counts exceeded 50×10^9/L. More impressively, after just one month, her fetal hemoglobin (HbF) levels surged, while sickle hemoglobin (HbS) levels saw a significant decline. By the third month post-treatment, the HbF-to-HbS ratio stabilized around 64, showcasing a promising turnaround in her condition.
CS-206 uses the novel transformer Base Editing (tBE) technology developed by the company's scientific co-founders, allowing for precise edits in the HBG1/2 promoter region of the patient’s autologous hematopoietic stem cells. This targeted approach mimics beneficial mutations found in healthy individuals, ultimately reactivating γ-globin expression.
The therapy’s ability to suppress red blood cell sickling significantly reduces the occurrence of VOCs and hemolysis. Unlike CRISPR-based methods, CS-206 functions without inducing double-strand breaks in DNA, mitigating risks of genomic deletions and off-target mutations. This accuracy makes it a safer choice, promptly resulting in increased fetal hemoglobin levels that effectively minimize red blood cell sickling—an essential factor in managing SCD.
Sickle cell disease is a hereditary hemoglobin disorder stemming from mutations of the β-globin gene, leading to severe complications including chronic anemia and pain crises. Approximately 3.5% of the global population carries this mutation, giving rise to around 300,000 births of infants affected by the disease each year. The prevalence of SCD is particularly high in regions such as Africa, the Mediterranean, and South Asia. SCD and β-thalassemia are among the most common monogenic inherited disorders worldwide.
CorrectSequence has already achieved success with its CS-101 therapy designed for β-thalassemia, curing patients from multiple countries, including China and Malaysia. As of May 2026, patients treated with CS-101 have remained transfusion-independent for over 15 months.
Currently, recruitment for the investigator-initiated trial of CS-206 is underway. CorrectSequence is actively intensifying its clinical development and plans to commercialize both CS-101 and CS-206, aiming to provide more effective and affordable therapies for hemoglobinopathy patients globally.
CorrectSequence Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative gene editing therapies using its proprietary transformer Base Editor. With initiatives spanning various genetic disorders and a commitment to precision medicine, CorrectSequence is at the forefront of advancing healthcare solutions.
For more information, visit CorrectSequence's website.
A Promising Treatment Approach
The patient underwent treatment in February 2025 and has remained free from VOCs and anemia for 13 consecutive months, achieving the primary efficacy endpoint set by the study. Following the engraftment of CS-206, the patient's hematologic profile improved dramatically. Neutrophils were detected as early as Day 13, and by Day 21, her platelet counts exceeded 50×10^9/L. More impressively, after just one month, her fetal hemoglobin (HbF) levels surged, while sickle hemoglobin (HbS) levels saw a significant decline. By the third month post-treatment, the HbF-to-HbS ratio stabilized around 64, showcasing a promising turnaround in her condition.
Safety and Precision of CS-206
CS-206 uses the novel transformer Base Editing (tBE) technology developed by the company's scientific co-founders, allowing for precise edits in the HBG1/2 promoter region of the patient’s autologous hematopoietic stem cells. This targeted approach mimics beneficial mutations found in healthy individuals, ultimately reactivating γ-globin expression.
The therapy’s ability to suppress red blood cell sickling significantly reduces the occurrence of VOCs and hemolysis. Unlike CRISPR-based methods, CS-206 functions without inducing double-strand breaks in DNA, mitigating risks of genomic deletions and off-target mutations. This accuracy makes it a safer choice, promptly resulting in increased fetal hemoglobin levels that effectively minimize red blood cell sickling—an essential factor in managing SCD.
Understanding Sickle Cell Disease
Sickle cell disease is a hereditary hemoglobin disorder stemming from mutations of the β-globin gene, leading to severe complications including chronic anemia and pain crises. Approximately 3.5% of the global population carries this mutation, giving rise to around 300,000 births of infants affected by the disease each year. The prevalence of SCD is particularly high in regions such as Africa, the Mediterranean, and South Asia. SCD and β-thalassemia are among the most common monogenic inherited disorders worldwide.
CorrectSequence has already achieved success with its CS-101 therapy designed for β-thalassemia, curing patients from multiple countries, including China and Malaysia. As of May 2026, patients treated with CS-101 have remained transfusion-independent for over 15 months.
Ongoing Clinical Development
Currently, recruitment for the investigator-initiated trial of CS-206 is underway. CorrectSequence is actively intensifying its clinical development and plans to commercialize both CS-101 and CS-206, aiming to provide more effective and affordable therapies for hemoglobinopathy patients globally.
About CorrectSequence
CorrectSequence Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative gene editing therapies using its proprietary transformer Base Editor. With initiatives spanning various genetic disorders and a commitment to precision medicine, CorrectSequence is at the forefront of advancing healthcare solutions.
For more information, visit CorrectSequence's website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.